Maier & Company
Corporate Communications and Investor Relations

                                                                    NEWS RELEASE

CONTACT:
                      Gary S. Maier
                      Maier & Company, Inc.
                      (310) 442-9852

            CYTOMEDIX, INC. CONSOLIDATES MANAGEMENT RESPONSIBILITIES
                  --PRESIDENT SCHEDULED TO RELINQUISH DUTIES--

      LITTLE ROCK, ARKANSAS - JUNE 29, 2004 - Cytomedix, Inc. (OTCBB:CYME) today
announced that Mark Cline, president, will leave the company this month and
Kshitij Mohan, Ph.D., chief executive officer, will assume his responsibilities
in a planned transition.

      "As our AutoloGel(TM) System for the treatment of chronic wounds becomes a
reality, our management requirements have changed and Mark has decided to leave
the company to pursue other endeavors. We appreciate Mark's contributions during
a critical period in the company's evolution and wish him well for his future
success," said Dr. Mohan.

      The company also said Cline has resigned as a member of its board of
directors.

ABOUT CYTOMEDIX

      Cytomedix, Inc. is a biotechnology company specializing in processes and
products derived from autologous platelet releasates. The current product
offering is Autologel(TM), an autologous platelet gel composed of multiple
growth factors and fibrin matrix, which is used to treat chronic wounds and
supported by an extensive base of patents. The Company is working with
healthcare providers to offer an advanced therapy at the point-of-care in
multiple settings. It has commenced a prospective, randomized, and controlled,
FDA- approved clinical trial to seek a specific clinical indication for
Autologel(TM)for the treatment of non-healing diabetic foot ulcers. Additional
information is available at: http://www.cytomedix.com.

FORWARD LOOKING STATEMENTS

      Statements contained in this press release not relating to historical
facts are forward-looking statements that are intended to fall within the safe
harbor rule for such statements under the Private Securities Litigation Reform
Act of 1995. The information contained in the forward-looking statements is
inherently uncertain, and Cytomedix's actual results may differ materially due
to a number of factors, many of which are beyond Cytomedix's ability to predict
or control, including among others, governmental regulation, acceptance by the
medical community and competition. These forward-looking statements are subject
to known and unknown risks and uncertainties that could cause actual events to
differ from the forward-looking statements. More information about some of these
risks and uncertainties may be found in the reports filed with the Securities
and Exchange Commission by Cytomedix, Inc.

                                      # # #